Work Here?
Overview
Owkin uses artificial intelligence to improve medical diagnostics and speed up the development of new drugs, specifically within the field of oncology. The company builds machine learning models that analyze diverse patient data, such as tissue samples and genetic records, to help researchers predict how patients will respond to specific treatments during clinical trials. Unlike many competitors, Owkin utilizes a collaborative network of academic centers and pharmaceutical companies to train its AI on vast, diverse datasets while maintaining strict data privacy. Their goal is to advance precision medicine by making the drug discovery process faster, less expensive, and more accurate for patients.
About Owkin
Industries
Data & Analytics
AI & Machine Learning
Biotechnology
Healthcare
Company Size
201-500
Company Stage
Late Stage VC
Total Funding
$368M
Headquarters
Paris, France
Founded
2016
Get referred to Owkin
See people who can refer or advise you
Simplify's Take
What believers are saying
- Boehringer signed September 2, 2026, expanding K Pro into cancer and immunology discovery.
- Sanofi's June 8, 2026 five-year K Pro license turns a 2021 partnership into platform revenue.
- Cleveland Clinic Abu Dhabi launched Aila on June 17, 2026, validating clinical deployment.
What critics are saying
- Owkin still depends on pharma licensing; no disclosed economics from Boehringer, AstraZeneca, or Sanofi.
- Patient-data sourcing creates privacy and consent exposure; one breach or objection breaks access.
- Waiv's March 12, 2026 spinout signals diagnostics monetization pressure and fragmented strategic focus.
What makes Owkin unique
- K Pro uses multimodal patient data from 800-plus hospitals, not generic foundation models.
- Owkin pairs AI agents with pathology, clinical, and trial workflows across oncology and immunology.
- Anthropic integration on January 12, 2026 made Pathology Explorer externally usable through MCP.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$368M
Above
Industry Average
Funded Over
9 Rounds
Benefits
Flexible Work Hours
Remote Work Options
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↑ 0%2 year growth
↑ 0%Owkin signs AI drug discovery deal with Boehringer for cancer, immunology. 02 Sep 2026 08:03PM (Updated: 02 Sep 2026 10:47PM) Add CNA as a trusted source to help Google better understand and surface our content in search results. Sept 2: AI company Owkin said on Wednesday it has signed a licensing deal with Germany's Boehringer Ingelheim, giving the drugmaker access to its AI research platform and patient data to speed up discovery of drugs for cancer and immunity-related diseases. The deal adds Boehringer to a growing list of drugmakers using Owkin's AI technology, "K Pro". AstraZeneca licensed it in May, while Sanofi expanded its partnership with a five-year agreement in June. Here are some more details: - The deal builds on the companies' pilot project in 2025, in which Owkin used its patient tumor samples and related biological datasets to help Boehringer prioritize potential drug targets, the AI company's CEO, Thomas Clozel, told Reuters. - Under the new pact, Owkin will license multimodal oncology data to Boehringer and will generate new data in immunology. - Owkin licenses, sources and generates patient data in collaboration with its global patient data network. - The companies did not disclose the financial terms of the agreement.
DeepCyte launches world's first single-cell mechanistic toxicity atlas as enterprise pharma pilots advance. Proprietary training dataset spanning 300,000 cells and ~100 compounds positions DeepCyte to transform preclinical toxicology with mechanism-based prediction Wilmington, DE and Copenhagen, Denmark /PRNewswire/ - DeepCyte Inc., a techbio company building AI toxicology tools for drug development, today announced the launch of DeeTox Atlas(TM), the world's first single-cell metabolomic reference atlas of drug toxicity mechanisms. Enterprise pilot programs with global pharmaceutical companies begin in the coming months. DeeTox Atlas(TM) is a foundation dataset built from two independent single-cell metabolomics perturbation studies, spanning approximately 100 toxicant compounds, 300,000 cells, and ~500 metabolites per cell - over 3,000 single-cell measurements per compound across six biological replicates. Each compound is mapped to a curated four-level hierarchy of toxicity mechanisms anchored to established Adverse Outcome Pathways (AOPs). Rather than generating new wet-lab data for every compound, DeepCyte trains a foundation model capable of predicting toxicity mechanisms for compounds it has never measured. As the atlas expands, the platform becomes increasingly scalable, reducing laboratory dependence while improving predictive performance. "AI in toxicology is only as good as the biological data it learns from. DeeTox Atlas lets us find subtle molecular patterns tied to key toxicity mechanisms - patterns our validation studies show are expressed in small subpopulations of cells and are effectively invisible to methods lacking single-cell resolution - and turn them into predictive models," said Theodore Alexandrov, Co-Founder and CEO of DeepCyte. "Our vision is to move toxicology from reactive laboratory testing toward predictive, mechanism-based AI that surfaces and explains safety liabilities earlier in drug discovery." The Atlas will expand with more compounds, mechanisms, and biochemical and clinical data, making predictions more actionable for toxicologists, medicinal chemists, and safety scientists. DeepCyte has also appointed Mona Lakkis as Senior Vice President of Partnerships. Formerly Senior Vice President & General Manager at Owkin, Lakkis will lead enterprise commercialization as DeepCyte advances pilots with three of the top 20 pharmaceutical companies. About DeepCyte DeepCyte is an AI-powered techbio company developing predictive toxicology solutions for drug discovery. By training mechanistic AI models on proprietary single-cell data, DeepCyte helps pharmaceutical companies predict toxicity mechanisms earlier, accelerating safer and more efficient therapeutic discovery. Like what you are reading?
Owkin to integrate Kognitic's clinical trial data into K Pro through new collaboration. NEW YORK & PARIS - Owkin, the agentic AI company pioneering Biological Artificial SuperIntelligence to revolutionize drug discovery and development, today announced a data collaboration with Kognitic to integrate Kognitic's clinical trial data into K Pro, Owkin's AI Scientist. The collaboration will initially focus on oncology and immunology, with the potential to expand into additional therapeutic areas and datasets over time. Kognitic structures global clinical trial signals into a normalized, decision-ready evidence layer for commercial, medical, and BD teams. These signals span trial registries, pipeline timelines, and competitive landscape data. Through this collaboration, Kognitic clinical data will be accessible directly within K Pro, giving decision-making teams a single source of data across fragmented feeds. K Pro combines multimodal patient data with specialized biological, agentic AI systems to support each stage of the pharmaceutical value chain. Bringing Kognitic's clinical trial data into that layer extends K Pro's reach into competitive intelligence and portfolio-decision use cases, alongside its existing biological and multimodal data capabilities. Thomas Clozel, MD, Co-founder and CEO, Owkin: Pharmaceutical decision-making depends on the best, structured, real-time data. Bringing Kognitic's clinical trial data into K Pro gives its partners a faster, more complete picture the moment they need it. Kimon Lounis, Director of Commercial Strategy & Partnerships, Kognitic: This partnership is a major milestone for Kognitic and for how clinical trial data can power advanced AI in life sciences. By bringing Kognitic's clinical trial data into K Pro, Owkin can support Owkin's AI Scientist with richer evidence for agentic workflows and biological reasoning. Jaseem Mahmmdla, Co-Founder and CEO, Kognitic: The next generation of AI in life sciences will be built through partnerships that combine best-in-class intelligence. Owkin has built an exceptional platform with K Pro, and together Owkin is bringing trusted clinical trial data into a unified environment to help pharmaceutical teams make faster, more informed decisions. About Owkin. Owkin is an agentic AI company pioneering Biological Artificial Superintelligence to solve problems in biology too challenging for human researchers alone. Owkin builds K Pro - an AI scientist that works alongside pharmaceutical research teams to power discovery and strategic decision-making. K Pro autonomously orchestrates a suite of AI skills and tools to decode complex biology and accelerate research, with scientists shaping every hypothesis, decision, and discovery. K Pro is built on Owkin's unrivalled multimodal patient data network, state-of-the-art AI for biology, and a decade of experience working hand-in-hand with pharmaceutical partners.
Owkin, Sanofi expand AI collaboration to build drug development AI agents. Posted: 20 june 2026 Owkin and Sanofi are expanding their artificial intelligence collaboration through a multi-year agreement to co-develop AI-enabled biopharma agents for drug research and development. Posted: 22 june 2026 Healthcare innovation continues to evolve at an extraordinary pace - driven by advances in AI, digital health, virtual care, and new models of medical education. At the centre of many of these conversations is Prof. Shafi Ahmed, its Chairman and... Posted: 19 june 2026 The trial marks the first time a vaccine whose active ingredient was entirely designed by AI has been tested in humans, researchers at the University of Cambridge in the U.K. The experimental jab is intended to be a "universal vaccine"...
Cleveland Clinic Abu Dhabi collaborates with Owkin to launch world's first clinical AI scientist. Faizan Hashmi Published June 17, 2026 | 02:30 PM ABU DHABI, (UrduPoint / Pakistan Point News / WAM - 17th Jun, 2026) Cleveland Clinic Abu Dhabi today announced a collaboration with Owkin to launch 'Aila,' the world's first clinical artificial intelligence scientist. The advanced AI platform is designed to support real-time clinical decision-making and accelerate medical research using real patient data. 'Aila' is designed to reason across complex datasets, generate actionable medical insights, and continuously learn. It transforms how clinicians interact with data - enabling faster, more informed, and more precise decision-making at the point of care. 'Aila' is designed to function as a clinical AI scientist, unlocking and connecting datasets. Through a secure, intuitive natural-language interface, physicians will be able to query vast amounts of clinical data in real time and receive insights that previously required days or weeks of manual analysis. The platform is expected to transform fragmented information into a unified, queryable knowledge layer that delivers meaningful insights at the critical moment when clinical decisions are made. "This collaboration reflects our commitment to innovation and our responsibility to actively create the future of healthcare," said Dr. Georges-Pascal Haber, Chief Executive Officer of Cleveland Clinic Abu Dhabi. "By responsibly harnessing advanced AI built on real patient data, we are empowering our caregivers with powerful tools that enhance clinical judgment, advance discovery, and ultimately improve outcomes for the patients and communities we serve." The initial deployment of 'Aila' will focus on prostate cancer, integrating multiple clinical data sources including electronic health records, physician notes, pathology reports, and medical imaging. Supported by the UAE's AI-enabled infrastructure and built on Owkin's agentic K Pro - purpose-built for biology platform, 'Aila' is engineered to scale across additional medical specialities and increasingly complex data modalities. Over time, the platform is designed to incorporate advanced data types such as multi-omics and genomic data, supporting large-scale precision medicine initiatives. Facebook Twitter Reddit Pinterest Whatsapp
Owkin is Hiring for 3 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Owkin
Industries
Data & Analytics
AI & Machine Learning
Biotechnology
Healthcare
Company Size
201-500
Company Stage
Late Stage VC
Total Funding
$368M
Headquarters
Paris, France
Founded
2016
Owkin is Hiring for 3 Jobs on Simplify!
Find jobs on Simplify and start your career today